AliveCor has reduced the price on its ECG monitor to $74.99 from $199; it's also now a third-generation device that is 50% thinner and 40% lighter.
This spring, CardioDx had readied itself again to make a run at an IPO. But it's opted to take another round of private investment instead. It has raised $35 million in equity from new investor Alberta Investment Management alongside existing investors.
A pair of European diagnostics companies have wrapped up venture financings. Autoimmune diagnostician Protagen had a first close of a €10 million ($12.5 million) financing, while cancer genomic diagnostics company, 14M Genomics, a spinout of the Wellcome Trust Sanger Institute, got £12.5 million ($19.6 million).
Diagnosing ear infections from home has come in the form of a smartphone accessory. Cellscope Oto is a clip-on otoscope, the tool doctors use to peer into infected ears, that attaches to a smartphone so a video or photo of the ear can be sent to the doctor's office without the patient leaving home.
Roche has launched the Laboratory-in-a-tube technology it acquired when it bought iQuum in April for $275 million up front and up to $175 million in milestone payments. Roche is making the system available in the U.S. and Europe.
Ortho-Clinical Diagnostics announced that the NephroCheck diagnostic test for acute kidney injury is now available nationwide to hospitals, marking another step forward for the product that put developer Astute Medical among this year's Fierce 15 med tech companies.
Abbott Laboratories snagged a CE mark for its molecular diagnostic platform for blood-related infections, continuing its diagnostics winning streak and moving the company one step closer to securing stateside approval for its product.
Point-of-care diagnostics company Welch Allyn and visual electrophysiology player LKC Technologies have signed an exclusive partnership for the former to distribute the latter's RETeval DR device, which screens for diabetic retinopathy.
The FDA gave HeartFlow de novo clearance Monday for its FFRCT technology, the first and only noninvasive imaging technology for coronary artery disease (CAD) that shows the extent of a blockage and how it affects blood flow. HeartFlow FFRCT could potentially change the way that CAD is diagnosed and managed.
A new study supports the effectiveness of 3-D mammography, which researchers found has the potential to significantly increase the rate of identifying cancer in women with dense breasts who are screened using the digital technology.